AlbrethsenJ., BogeboR., GammeltoftS.: Upregulated expression of human neutrophil peptides 1-2 and 3 in colon cancer serum and tumors: a biomarker study.BMC Cancer, 5: 8, 2005.
3.
MelleC., ErnstG., SchimmelB.: Discovery and identification of alpha-defensins as low abundant, tumor-derived serum markers in colorectal cancer.Gastroenterology, 129: 66–73, 2005.
4.
BarrierA., BoelleP.Y., RoserF.: Stage II colon cancer prognosis prediction by tumor gene expression profiling.J Clin Oncol, 24: 4685–4691, 2006.
5.
EschrichS., YangI., BloomG.: Molecular staging for survival prediction of colorectal cancer patients.J Clin Oncol, 23: 3526–3535, 2005.
6.
ArnoldD., SiewczynskiR., SchmollJ.: The integration of targeted agents into systemic therapy of metastatic colorectal cancer.Ann Oncol, 17 (Suppl 10): xl22–xl28, 2006.
7.
SastreJ., ArandaE., GravalosC.: Single-agent cetuximab as first-line treatment for elderly patients with advanced colorectal cancer. Preliminary results of a phase II study.Ann Oncol, 17 (Suppl 10): abstr 324, 2006.
8.
PessinoA., ArtaleS., GuglielmiS.: First-line single agent cetuximab in patients with advanced colorectal cancer.Proc ASCO, abstr 3553, 2006.
9.
HelblingD., BornerM., MingroneW.: The effect of cetuximab on the XELOX combination in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss group for Clinical Cancer Research (SAKK): trial SAKK 41/04.Ann Oncol,17 (Suppl 10): abstr 328, 2006.
10.
Fischer von WeikersthalL., MoosmannN., Veh-ling-KaiserU.: Cetuximab plus capecitabine/irinotecan (XELIRI) vs cetuximab plus capecitabine/oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer (CRC): a randomized trial of the AIO CRC study Group.Ann Oncol, 17 (Suppl 10): abstr 3270, 2006.
11.
Diaz RubioE., TaberneroJ., van CutsemE.: Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: an international phase II study.Proc ASCO, abstr 3535, 2005.
12.
VenookA., NiedzwieckiD., HollisD.: Phase III study of FOLFIRI or FOLFOX +/- cetuximab for patients with untreated metastatic adenocarcinoma of the colon or rectum: CALGB 80203 preliminary results.Proc ASCO, abstr 3509, 2006.
13.
PeetersM.: A phase III multicenter, randomized controlled trial of panitumumab plus BSC versus BSC alone in patients with metastatic colorectal cancer.AACR Annual Meeting, abstr CP-1, 2006.
14.
HumbletY., Van CutsemE., PeetersM.: Panitumumab for the treatment of metastatic colorectal cancer (mCRC): a multicenter study in patients who failed chemotherapy and best supportive care.Ann Oncol, 17 (Suppl 10): abstr 3250, 2006.
15.
CunninghamD., HumbletY., SienaS.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.N Engl J Med, 351: 337–345, 2004.
16.
TejparS., PeetersM., HumbletY.: Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): preliminary data.Proc ASCO, abstr 3554, 2006.
17.
CassidyJ.: First efficacy and safety results from XELOX-1/N016966, a randomised 2×2 factorial phase III trial of XELOX vs FOLFOX4 + bevaci-zumab or placebo in first-line metastatic colorectal cancer.ESMO2006 Presidential Symposium.
18.
HurwitzH., FehrehnbacherL., NovotnyW.: Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer.N Engl J Med2004; 350: 2335–2342.
19.
BursiS., MasiG., AntonuzzoA.: Capecitabine in combination with oxaliplatin and irinotecan (XELOXIRI) in patients with metastatic colorectal cancer: preliminary results of a pilot study by GONO.Ann Oncol,17 (Suppl 10): abstr 350P, 2006.
20.
MarounJ.A., JonkerD., GoelR.: A phase I/II study of capecitabine, irinotecan and oxaliplatin as first line therapy in patients with advanced or metastatic colorectal cancer.Ann Oncol, 17 (Suppl 10): abstr 341P, 2006.
21.
BornerM.: Lack of infusion reaction with panitumumab in a patient who experienced an infusion reaction with cetuximab.Ann Oncol, 17 (Suppl 10): abstr 360P, 2006.
